SVNT Related Analyst Comments

Apr 20, 2012 10:05 AM Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

Feb 2, 2012 01:46 PM Jefferies Maintains an 'Underperform' on Savient Pharmaceuticals (SVNT); CEO Resigns After Short Tenure

Jun 22, 2011 07:59 AM Citadel Securities Maintains a 'Neutral' on Savient Pharmaceuticals (SVNT); Ilaris FDA Panel Rejection Removes Potential Krystexxa Adoption Overhang

Dec 29, 2010 09:42 AM Soleil Securities Calls Savient Pharmaceuticals (SVNT) CEO Search An Important Step in the Right Direction

Dec 29, 2010 09:34 AM Wedbush Said Savient Pharmaceuticals' (SVNT) CEO Search Could Suggest Near-Term Sale Is Off the Table

Dec 1, 2010 09:25 AM Global Hunter Securities Reiterates a 'Buy' on Savient Pharmaceuticals (SVNT); Stock Significantly Undervalued

Oct 26, 2010 03:52 PM Global Hunter Securities Cuts Price Target on Savient Pharmaceuticals (SVNT) to $15, But Maintains 'Buy'

Sep 16, 2010 08:32 AM Global Hunter Securities Reiterates a 'Buy' on Savient Pharmaceuticals (SVNT); Acquisition Talks Continue; No Salesforce Identified Yet

Sep 15, 2010 02:40 PM Savient (SVNT): FDA Approval "Check", M&A Next

Sep 15, 2010 02:38 PM Leerink Swann Raises Target on Savient (SVNT) to $22; Highlights Takeover Potential Following Krystexxa Approval

Sep 15, 2010 01:47 PM Wedbush Maintains an 'Outperform' on Savient Pharmaceuticals (SVNT); Raising PT on Potential Takeout in the Near Term

Jul 12, 2010 12:14 PM Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)

Jun 29, 2010 03:45 PM Global Hunter Securities Suggest Investors Acquire a Basket of Biotech Stocks

Aug 3, 2009 03:07 PM Savient Pharma (SVNT) Lower On FDA Refusal of Gout Treatment, But Analysts Still Positive

Jul 31, 2009 09:12 AM Wedbush Morgan Comments On Savient (SVNT) Ahead of FDA PDUFA Date

Jan 8, 2007 07:22 AM Cramer's Top Speculative Stocks for 2007: SVNT, RAD, LVLT